Bristol Myers Squibb
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, is headquartered in the United Arab Emirates (AE) and operates extensively across North America, Europe, and Asia. Founded in 1887, BMS has a rich history marked by significant milestones in drug development and innovation. Specialising in oncology, immunology, cardiovascular diseases, and fibrosis, Bristol Myers Squibb is renowned for its unique portfolio of therapies, including groundbreaking treatments like Opdivo and Eliquis. These products are distinguished by their advanced mechanisms of action and proven efficacy, positioning BMS as a frontrunner in the pharmaceutical industry. With a commitment to research and development, Bristol Myers Squibb has achieved notable recognition, consistently ranking among the top biopharmaceutical companies globally. Its dedication to improving patient outcomes underscores its pivotal role in transforming healthcare.
DitchCarbon Score
How does Bristol Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol Myers Squibb's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol Myers Squibb's reported carbon emissions
In 2020, Bristol Myers Squibb reported total carbon emissions of approximately 289,930 kg CO2e. This figure includes 165,340 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 112,700 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company recorded 11,890 kg CO2e in Scope 3 emissions, specifically from business travel. Comparatively, emissions in previous years were higher, with 339,880 kg CO2e in 2019 and 375,360 kg CO2e in 2018. This indicates a significant reduction in total emissions over the two-year period, showcasing Bristol Myers Squibb's commitment to lowering its carbon footprint. Despite these reductions, there are currently no specific science-based targets (SBTi) or documented climate pledges outlined in their initiatives. The emissions data is cascaded from the parent company, Bristol-Myers Squibb Company, reflecting the company's ongoing efforts to address climate change within its operational framework. Bristol Myers Squibb continues to focus on sustainability and environmental responsibility, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|---|
| Scope 1 | 210,540 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 150,790 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 69,630 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol Myers Squibb is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
